On the Philips Respironics CPAP recall, no court has decided whether the conduct was ordinary negligence or gross negligence — the question was settled rather than adjudicated. The strongest argument for gross negligence rests on documented prior knowledge: regulators recorded that the company knew about the foam problem years before it told users, which is the kind of fact that moves a claim from carelessness toward conscious disregard. That distinction matters because gross negligence is what unlocks punitive damages in most states, and punitive damages are often the largest number in a product case. Below is what the record actually shows, what it does not show, and what a device user with respiratory complaints can still do.
Official resources:
- Read the original report from FDA — Use this primary source to review the complete report.
- Read the official notice from FDA — Use this primary source to verify the official announcement.
Table of Contents
- What the recall was and what users reported
- Negligence versus gross negligence in plain terms
- The prior-knowledge evidence that pushes toward the higher standard
- The limits a careful reader should weigh
- What a device user with respiratory symptoms can do now
- Frequently Asked Questions
What the recall was and what users reported
Philips Respironics began a voluntary US recall on June 14, 2021, covering certain CPAP machines (devices that push pressurized air through a mask to treat sleep apnea), BiPAP units and ventilators. The problem was the polyester-based polyurethane sound abatement foam inside the housing, installed to quiet the motor. According to the FDA's safety communication, that foam can break down into particles or release chemicals that a user then inhales or swallows.
The reported harms track closely with what people describe when they contact a lawyer. FDA lists headache, upper-airway irritation, cough, chest pressure, sinus infection, dizziness, irritation of the eyes, nose and skin, hypersensitivity reactions, nausea and vomiting, and possible toxic and carcinogenic effects. The volume is substantial. As of its January 31, 2024 update, FDA said it had received more than 116,000 medical device reports since April 2021 reportedly associated with foam breakdown, including 561 reports of death, with reported injuries including cancer, pneumonia, asthma, infection, shortness of breath, nodules and chest pain.
Negligence versus gross negligence in plain terms
Ordinary negligence is a failure to use reasonable care. A manufacturer that should have caught a defect through adequate testing, and did not, is negligent. The remedy is compensatory damages: medical bills, lost income, pain and suffering. Gross negligence is a different animal.
Most states describe it as conduct showing a conscious or reckless disregard for a known risk — not a missed problem, but a recognized problem left unaddressed. Some jurisdictions use related labels: willful and wanton conduct, or reckless indifference. The practical stake is punitive damages, which exist to punish rather than to compensate. Nearly every state requires something more than ordinary negligence before a jury may award them, and many require clear and convincing evidence of it. So the negligence-or-gross-negligence line is not academic wording — it determines whether the ceiling on a case is the plaintiff's actual losses or something well above them.
The prior-knowledge evidence that pushes toward the higher standard
The single most-cited document is FDA's Form 483, issued after an August–November 2021 inspection of the Murrysville, Pennsylvania plant. That inspection report records that on or about November 25, 2015, the firm knew of a preventive-maintenance procedure another Philips entity had adopted in response to foam degradation complaints — and that "no further investigation, health hazard evaluation, risk analysis, or design review was performed, or documented." FDA's proposed repair-and-replace order under section 518(b) of the Food, Drug, and Cosmetic Act adds the volume behind that knowledge.
The agency's filing states that Philips' own analysis found 110 foam-degradation complaints received between 2014 and 2017, hundreds of confirmed foam-degradation complaints across affected products from 2014 to 2019, and that testing performed for Philips in 2016 determined the foam was susceptible to degradation. That is the shape of a gross-negligence theory: a known failure mode, internal test results confirming it, a sister company already mitigating it, and six years before a recall. A plaintiff's lawyer would argue the company did not merely fail to discover the risk — it chose not to look harder at one it had already found.
The limits a careful reader should weigh
Two things cut against the strongest version of that argument. First, reporting volume is not proof of causation. FDA notes that only 30 medical device reports tied to foam breakdown were submitted between 2011 and April 2021, none reporting patient injury or death, and that the 116,000-report figure followed the recall publicity. FDA's own problems-reported page cautions that device reports do not establish that a device caused an event.
Second, nothing in the regulatory record is a liability finding. On April 9, 2024, the US District Court for the Western District of Pennsylvania entered a consent decree of permanent injunction against Philips RS North America and affiliated entities, barring production and sale of new CPAP and BiPAP devices at named US facilities until FDA gives written notice of compliance, and requiring a Recall Remediation Plan and an independent testing expert. But the Justice Department stated that the resolved claims "are allegations only" and that "there has been no determination of liability." The personal injury litigation ended the same way. Philips agreed in April 2024 to pay $1.075 billion to resolve personal injury claims in the federal MDL and the Massachusetts state cases, under a master agreement expressly made without admitting "any fault or liability, or that any injuries were caused by Respironics' devices." The private settlement required no court approval. So the honest answer to the title question is that the evidence supports pleading gross negligence, a $1.075 billion resolution is consistent with real exposure, and no fact-finder ever ruled on it.
What a device user with respiratory symptoms can do now
The settlement's existence does not mean a given person's claim is live, closed, or worth anything in particular. These steps establish the facts any evaluation turns on: One warning worth stating plainly: a settlement that resolves claims without a liability finding typically includes release language, and signing a release ends the claim regardless of what later evidence emerges. Read what a claim form releases before returning it, and have someone who does not stand to earn a fee from the quick resolution explain it.
- Identify the exact device — model name, model number and serial number, from the label on the unit itself, not the box.
- Keep the machine if you still have it. A physical device with its original foam is evidence; returning or discarding it removes the one object a testing expert can examine.
- Pull the prescription and supply records showing when you started using it and for how long. Duration of exposure drives damages more than any single symptom.
- Get the respiratory complaints documented in a medical chart with dates, including any imaging, pulmonary function testing or biopsy results.
- Ask a lawyer specifically about the statute of limitations in your state and whether participation in, or exclusion from, the 2024 personal injury settlement affects you.
Frequently Asked Questions
Does the $1.075 billion settlement mean Philips was found grossly negligent?
No. The master settlement agreement, dated May 9, 2024, expressly denies any fault or liability and denies that the devices caused injuries. It was a private agreement that required no court approval, so the gross-negligence question was never put to a judge or jury.
Are punitive damages still available in CPAP cases?
Punitive damages require proof of conduct beyond ordinary negligence, usually by clear and convincing evidence, and the standard varies by state. Because the main litigation resolved by agreement, no punitive award was tried. Whether any remains available depends on your state's law, your limitations period, and whether you are bound by a release.
Why does the 561 figure appear as "reports of death" rather than deaths caused by the foam?
Medical device reports are submissions from users, clinicians and manufacturers. FDA states they do not establish that a device caused the reported event, and that reporting rose sharply after recall publicity. The number shows the scale of concern, not a causation finding.
Can the company sell these devices again?
Under the April 2024 consent decree, Philips is barred from producing and selling new CPAP and BiPAP devices at the named US facilities until FDA provides written notice that it has come into compliance. Servicing obligations for existing devices were handled separately through the required Recall Remediation Plan.
You Might Also Like
- A Pacemaker Recall Affecting Dependent Patients: Does the Conduct Rise From Negligence to Gross Negligence?
- A Hernia Mesh Implant Followed by Revision Surgery: Does the Conduct Rise From Negligence to Gross Negligence?
- A Defibrillator Failing During a Cardiac Emergency: Does the Conduct Rise From Negligence to Gross Negligence?